Immunothérapie: une nouvelle arme contre le cancer de la prostate [Immunotherapy: a therapeutic revolution against prostate cancer?].

Détails

ID Serval
serval:BIB_872CCC33F242
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Immunothérapie: une nouvelle arme contre le cancer de la prostate [Immunotherapy: a therapeutic revolution against prostate cancer?].
Périodique
Revue Médicale Suisse
Auteur(s)
Pracht M., Herrera F., Tawadros T., Berthold D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2013
Volume
9
Numéro
387
Pages
1070-1075
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Résumé
The interaction between the immune system and cancer was an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of sipuleucel-T and ipilimumab stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies under development are therapeutic vaccination strategies, such as sipuleucel-T and PROSTVAC-VF, or immune checkpoint blockade of CTLA-4. Improved understanding of the immune responses generated by the development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide new treatment options in prostate cancer.
Mots-clé
Humans, Immunotherapy, Male, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/immunology
Pubmed
Création de la notice
19/09/2013 21:15
Dernière modification de la notice
03/03/2018 19:01
Données d'usage